Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Inflammatory Biomarkers in Sputum Predict COPD Exacerbations.

Tufvesson, Ellen LU ; Ekberg, Marie LU and Bjermer, Leif LU (2013) In Lung 191(4). p.413-416
Abstract
INTRODUCTION: Exacerbations in chronic obstructive pulmonary disease (COPD) reduce quality of life and are associated with a more rapid deterioration of the disease. It is desirable to predict an oncoming exacerbation before it occurs. The aim of the present study was to identify biomarkers that may predict a forthcoming exacerbation. MATERIALS AND METHODS: Forty-three patients with COPD in their stable state were included and followed up monthly until exacerbation, or for a maximum of 6 months. The patients come for an extra visit (prior to a scheduled visit) when exacerbated. The patients completed the questionnaires CCQ and MRC. Exhaled breath condensate (EBC) was collected followed by spirometry, impulse oscillometry, and sputum... (More)
INTRODUCTION: Exacerbations in chronic obstructive pulmonary disease (COPD) reduce quality of life and are associated with a more rapid deterioration of the disease. It is desirable to predict an oncoming exacerbation before it occurs. The aim of the present study was to identify biomarkers that may predict a forthcoming exacerbation. MATERIALS AND METHODS: Forty-three patients with COPD in their stable state were included and followed up monthly until exacerbation, or for a maximum of 6 months. The patients come for an extra visit (prior to a scheduled visit) when exacerbated. The patients completed the questionnaires CCQ and MRC. Exhaled breath condensate (EBC) was collected followed by spirometry, impulse oscillometry, and sputum induction. RESULTS: Twenty-five patients had an exacerbation within the 6-month period. Leukotriene B4 in sputum was the only biomarker that was increased at the visit prior to exacerbation compared to at the stable phase (p = 0.05). There also was a tendency for a similar but not significant increase in the sputum levels of 8-isoprostane, myeloperoxidase activity, and interleukin-8, as well as additional increases during exacerbation. Sputum purulence was not increased until exacerbation (p = 0.02). In contrast, none of the inflammatory biomarkers in EBC, the quality-of-life questionnaire score, CRP, spirometric parameters, or impulse oscillometry parameters were increased at the visit prior to exacerbation compared to the values at the stable phase. CONCLUSION: Sputum biomarkers, especially leukotriene B4, could be used as predictors of a forthcoming exacerbation and worsening of COPD. This would be of great value for the patient, who may be a subject for early treatment and thereby avoid a progression of the disease. (Less)
Please use this url to cite or link to this publication:
author
; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Lung
volume
191
issue
4
pages
413 - 416
publisher
Springer
external identifiers
  • wos:000321916800014
  • pmid:23689877
  • scopus:84880795721
  • pmid:23689877
ISSN
1432-1750
DOI
10.1007/s00408-013-9473-5
language
English
LU publication?
yes
id
b181dbe9-ea6c-4459-87c3-1f40860a46c0 (old id 3804328)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23689877?dopt=Abstract
date added to LUP
2016-04-01 10:30:45
date last changed
2022-01-25 23:54:22
@article{b181dbe9-ea6c-4459-87c3-1f40860a46c0,
  abstract     = {{INTRODUCTION: Exacerbations in chronic obstructive pulmonary disease (COPD) reduce quality of life and are associated with a more rapid deterioration of the disease. It is desirable to predict an oncoming exacerbation before it occurs. The aim of the present study was to identify biomarkers that may predict a forthcoming exacerbation. MATERIALS AND METHODS: Forty-three patients with COPD in their stable state were included and followed up monthly until exacerbation, or for a maximum of 6 months. The patients come for an extra visit (prior to a scheduled visit) when exacerbated. The patients completed the questionnaires CCQ and MRC. Exhaled breath condensate (EBC) was collected followed by spirometry, impulse oscillometry, and sputum induction. RESULTS: Twenty-five patients had an exacerbation within the 6-month period. Leukotriene B4 in sputum was the only biomarker that was increased at the visit prior to exacerbation compared to at the stable phase (p = 0.05). There also was a tendency for a similar but not significant increase in the sputum levels of 8-isoprostane, myeloperoxidase activity, and interleukin-8, as well as additional increases during exacerbation. Sputum purulence was not increased until exacerbation (p = 0.02). In contrast, none of the inflammatory biomarkers in EBC, the quality-of-life questionnaire score, CRP, spirometric parameters, or impulse oscillometry parameters were increased at the visit prior to exacerbation compared to the values at the stable phase. CONCLUSION: Sputum biomarkers, especially leukotriene B4, could be used as predictors of a forthcoming exacerbation and worsening of COPD. This would be of great value for the patient, who may be a subject for early treatment and thereby avoid a progression of the disease.}},
  author       = {{Tufvesson, Ellen and Ekberg, Marie and Bjermer, Leif}},
  issn         = {{1432-1750}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{413--416}},
  publisher    = {{Springer}},
  series       = {{Lung}},
  title        = {{Inflammatory Biomarkers in Sputum Predict COPD Exacerbations.}},
  url          = {{http://dx.doi.org/10.1007/s00408-013-9473-5}},
  doi          = {{10.1007/s00408-013-9473-5}},
  volume       = {{191}},
  year         = {{2013}},
}